79623

GALNT14

GALNT15|GalNac-T10|GalNac-T14;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 14 (GalNAc-T14);GALNT14;UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 14 (GalNAc-T14)

UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 14|UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase T10|UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase T14|polypeptide GalNAc transferase 14|polypeptide N-acetylgalactosaminyltrans

2p23.1

protein-coding

Previously, a pilot genome-wide association study has identified candidate single nucleotide polymorphism predictors for the therapeutic response of 5-fluorouracil, mitoxantrone, and cisplatin (FMP) combination chemotherapy in advanced hepatocellular carcinoma (HCC). Here, we conducted a prospective confirmatory study to examine the predictive value of rs9679162 (located on GALNT14 gene) for the therapeutic responses using a split-dose FMP protocol. Onehundred and seven advanced HCC patients receiving split-dose FMP therapy were enrolled. ALL patients were in Barcelona Clinical Liver cancer Stage C with either main portal vein thrombosis and/or distant metastasis. Of them, 105 (98.1%) were child-Pugh classification B. GALNT14 genotype was determined beforetherapy. Of the patients included, 28 were rs9679162 "TT" and 79 were "non-TT" ("GG"+"GT") genotype. The median overall survival, time-to-progression, responserate, and disease control rate were ("TT" versus "non-TT") 6.8 versus 3.9 months(P < 0.001), 3.9 versus 2.1 months (P < 0.001), 28.6% versus 10.1% (P = 0.029), and 35.7% versus 15.2% (P = 0.030), respectively. Multivariate analysis indicated that rs9679162 genotype was an independent predictor for overall survival (P = 0.002). Categorical analysis showed that 17 patients with "TT" genotype, tumor size < 10 cm, and neutrophils < 74% had a median overall survival of 25.5 monthsand a therapeutic response rate of 47.1%. In conclusion, this prospective study confirmed that GALN14 genotype (rs9679162) was an effective predictor for therapeutic outcome in advanced HCC patients treated by FMP chemotherapy. Combining GALNT14 genotype and clinical parameters, a subgroup of patients with excellent outcome was identified. (c) 2013 Wiley Periodicals, Inc.#CI- Copyright (c) 2013 UICC.